骨转移癌微环境与治疗靶点

doi:10.3760/cma.j.issn.1673-422X.2014.11.017

摘要/Abstract

摘要： 目前骨转移癌的治疗手段相当有限,且疗效不显著。骨转移癌靶向治疗研究是当前的热点，同时也是难点。对骨微环境中成骨细胞、破骨细胞及肿瘤细胞等相互关系的最新研究成果，可为临床上治疗骨转移癌提供新的思路和方法。

Abstract: Microenvironment and therapeutic targets of metastatic bone cancerYang Jielai, Yang Qingcheng.Corresponding author:【Abstract】Currently, the treatment of bone metastases is quite limited,and the effect is not significant.It is a tempting but difficult task to find valid therapy.The recent research on bone microenvironment, including the osteoblasts, osteoclasts and tumor cells et al,may provide new targets and methods for the treatment of bone metastases.

Key words: Neoplasm metastasis, Bone tissue, Targeted therapy

杨接来, 杨庆诚. 骨转移癌微环境与治疗靶点[J]. 国际肿瘤学杂志, 2014, 41(11): 854-857.

YANG Jie-Lai, YANG Qing-Cheng. Microenvironment and therapeutic targets of metastatic bone cancer[J]. Journal of International Oncology, 2014, 41(11): 854-857.

参考文献

［1］ Suva LJ, Washam C, Nicholas RW, et al. Bone metastasis: mechanisms and therapeutic opportunities［J］. Nat Rev Endocrinol, 2011, 7(4): 208218. ［2］ Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required?［J］. Cancer Res, 2010, 70(14):56705673. ［2］ Cupp ME, Nayak SK, Adem AS, et al. Parathyroid hormone (PTH) and PTHrelated peptide domains contributing to activation of different PTH receptormediated signaling pathways［J］. J Pharmacol Exp Ther, 2013, 345(3):404418. ［3］ Christopher MJ, Liu F, Hilton MJ, et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokineinduced mobilization［J］. Blood , 2009, 114(7):13311339. ［4］ Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow［J］. J Clin Invest, 2011, 121(4):12981312. ［5］ Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGFlike ligands in an osteolytic signaling cascade for bone metastasis［J］. Genes Dev, 2009, 23(16):18821894. ［6］ Nannuru KC, Futakuchi M, Varney ML, et al. Matrix metalloproteinase (MMP)13 regulates mammary tumorinduced osteolysis by activating MMP9 and transforming growth factorbeta signaling at the tumorbone interface［J］. Cancer Res, 2010, 70(9):34943504. ［7］ Shevde LA, Das S, Clark DW, et al. Osteopontin: an effector and an effect of tumor metastasis［J］. Curr Mol Med, 2010, 10(1):7181. ［8］ Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression［J］. Nat Rev Cancer, 2010, 10(6):415424. ［9］ Dunn LK, Mohammad KS, Fournier PG, et al. Hypoxia and TGFbeta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment［J］. PLoS One, 2009, 4(9):e6896. ［10］ Korpal M, Yan J, Lu X, et al. Imaging transforming growth factorbeta signaling dynamics and therapeutic response in breast cancer bone metastasis［J］. Nat Med, 2009, 15(8):960966. ［11］ Ooi LL, Zhou H, Kalak R, et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis［J］. Cancer Res， 2010, 70(5):18351844. ［12］ Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure［J］. J Bone Miner Res, 2010, 25(3):440446. ［13］ Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial［J］. Lancet Oncol, 2010, 11(5):421428. ［14］ Hoffmann O, Aktas B, Goldnau C, et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study［J］. Anticancer Res, 2011, 31(10):36233628. ［15］ Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study［J］. J Clin Oncol, 2010, 28(35):51325139. ［16］ GonzalezSuarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestininduced mammary epithelial proliferation and carcinogenesis［J］. Nature, 2010, 468(7320):103107. ［17］ Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4week, doubleblind, randomized, controlled trial［J］. Clin Breast Cancer, 2010, 10(6):452458. ［18］ Shepard DR, Dreicer R. Zibotentan for the treatment of castrateresistant prostate cancer［J］. Expert Opin Investigig Drugs, 2010, 19(7):899908. ［19］ Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100［J］. Blood, 2009, 113(24):62066214. ［20］ Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy［J］. Blood, 2009, 113(18):43414351. ［21］ Wang SH, Lin SY. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention［J］. Exp Hematol Oncol, 2013, 2(1):2936. ［22］ Korpal M, Kang Y. Targeting the transforming growth factorbeta signalling pathway in metastatic cancer［J］. Eur J Cancer, 2010, 46(7):12321240. ［23］ Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGFbeta signaling by 1D11 antibody treatment increases bone mass and quality in vivo［J］. J Bone Miner Res, 2010, 25(11):24192426. ［24］ Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce antiangiogenic, antitumour and antiresorptive effects in experimental breast cancer bone metastases［J］. Eur J Cancer, 2011, 47(2):277286. ［25］ Mellick AS, Plummer PN, Nolan DJ, et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth［J］. Cancer Res, 2010, 70(18):72737282. ［26］ Li K, Dias SJ, Rimando AM, et al. Pterostilbene acts through metastasisassociated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer［J］. PLos One, 2013, 8(3):e57542.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[8]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[9]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[10]	王婷, 李文倩, 解友邦. 低氧与急性髓系白血病细胞氧感受通路的相关性[J]. 国际肿瘤学杂志, 2023, 50(8): 503-507.
[11]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[15]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.